Company Quick10K Filing
Quick10K
Biostar Angel Stem Cell
10-Q 2018-09-30 Quarter: 2018-09-30
10-Q 2018-06-30 Quarter: 2018-06-30
10-Q 2018-03-31 Quarter: 2018-03-31
10-K 2017-12-31 Annual: 2017-12-31
10-Q 2017-09-30 Quarter: 2017-09-30
8-K 2018-07-02 Officers, Exhibits
8-K 2018-01-15
8-K 2018-01-08
ELTP Elite Pharmaceuticals 50
SEII Sharing Economy International 32
GKIT Greenkraft 9
ENCR Ener-Core 2
DTHR Dthera Sciences 1
UMHL Umatrin Holding 0
VIST Vist Financial 0
SGLDF Shoal Games 0
PING Ping Identity 0
VNUE VNUE 0
BASC 2018-09-30
Part I Financial Information
Item 1. Financial Statements
Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Item 4. Controls and Procedures. Disclosures and Procedures
Part II Other Information
Item 1. Legal Proceedings
Item 1A. Risk Factors
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
Item 3. Defaults Upon Senior Securities
Item 4. Mine Safety Disclosures
Item 5. Other Information
Item 6. Exhibits
EX-31.1 ex31-1.htm
EX-31.2 ex31-2.htm
EX-32.1 ex32-1.htm

Biostar Angel Stem Cell Earnings 2018-09-30

BASC 10Q Quarterly Report

Balance SheetIncome StatementCash Flow

10-Q 1 form10-q.htm

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

FORM 10-Q

 

(Mark One)

 

[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended September 30, 2018

 

OR

 

[  ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from _______ to _______

 

Commission file number: 000-55810

 

BIOSTAR ANGEL STEM CELL CORPORATION

(Exact name of registrant as specific in its charter)

 

Delaware   82-1873024

(State or other jurisdiction of

Incorporation or organization)

 

(I.R.S. Employer

Identification Number)

 

419 Hindry Avenue, Suite E

Inglewood, California 90301

(Address of principal executive offices, including zip code)

 

(424) 227-9568

(Registrant’s telephone number, including area code)

 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [  ]

 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes [  ] No [X]

 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

 

  Large accelerated filer [  ] Accelerated Filer [  ]
  Non-accelerated filer [  ] Smaller reporting company [X]
    Emerging growth company [  ]

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [  ]

 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes [X] No [  ]

 

As of November 14, 2018, there were 10,980,000 shares of common stock outstanding.

 

 

 

 
 

 

BIOSTAR ANGEL STEM CELL CORPORATION

Form 10-Q

For the quarterly period ended September 30, 2018

 

TABLE OF CONTENTS

 

PART I. FINANCIAL INFORMATION  
   
Item 1 Financial Statements  
   
Balance Sheets as of September 30, 2018 (unaudited) and December 31, 2017 3
   
Statements of Operations for the Three and Nine Months Ended September 30, 2018, for the Three Months Ended September 30, 2017, and for the Period from May 17, 2017 (Inception) to September 30, 2017 (unaudited) 4
   
Statements of Cash Flows for the Nine Months Ended September 30, 2018 and for the Period from May 17, 2017 (Inception) to September, 2017 (unaudited) 5
   
Notes to Financial Statements (unaudited) 6
   
Item 2 Management’s Discussion and Analysis of Financial Condition and Results of Operations 10
   
Item 3 Quantitative and Qualitative Disclosures About Market Risk 12
   
Item 4 Controls and Procedures 12
   
PART II. OTHER INFORMATION  
   
Item 1 Legal Proceedings 13
   
Item 2 Unregistered Sales of Equity Securities and Use of Proceeds 13
   
Item 3 Defaults upon Senior Securities 13
   
Item 4 Mine Safety Disclosures 13
   
Item 5 Other Information 13
   
Item 6 Exhibits 13
   
Signatures 14

 

2
 

 

PART I FINANCIAL INFORMATION

 

ITEM 1. FINANCIAL STATEMENTS

 

BIOSTAR ANGEL STEM CELL CORPORATION

(FORMERLY LILY GROVE ACQUISITION CORPORATION)

BALANCE SHEETS

 

 

 

   September 30, 2018   December 31, 2017 
   (Unaudited)     
ASSETS          
           
CURRENT ASSETS:          
Cash and cash equivalents  $360,347   $- 
Due from a related party   1,550      
Prepaid expenses   3,052      
           
Total current assets  $364,949   $- 
           
TOTAL  $364,949   $- 
           
LIABILITIES AND STOCKHOLDERS’ DEFICIENCY          
           
CURRENT LIABILITIES:          
Due to related parties  $1,665   $- 
Loan from an affiliate   500,000      
Accrued liabilities   27,831    3,000 
           
Total current liabilities  $529,496   $3,000 
           
STOCKHOLDERS’ DEFICIENCY:          
           
Preferred stock, $0.0001 par value; 20,000,000 shares authorized; 10,000,000 and no shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively   1,000    - 
           
Common stock, $0.0001 par value; 100,000,000 shares authorized; 10,980,000 and 20,000,000 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively   1,098    2,000 
           
Additional paid-in capital   5,262    312 
           
Accumulated deficit   (171,907)   (5,312)
           
Total stockholders’ deficiency   (164,547)   (3,000)
           
TOTAL  $364,949   $- 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

3
 

 

BIOSTAR ANGEL STEM CELL CORPORATION

(FORMERLY LILY GROVE ACQUISITION CORPORATION)

STATEMENTS OF OPERATIONS

(UNAUDITED)

 

 

 

            For the period from 
   For the three
months ended
   For the three
months ended
   For the nine
months ended
   May 17, 2017
(inception) to
 
   September 30,
2018
   September 30,
2017
   September 30,
2018
   September 30,
2017
 
REVENEUE  $-    -   $-   $- 
                     
COST OF REVENUE   -    -    -    - 
                     
GROSS PROFIT   -         -    - 
                     
OPERATING EXPENSES   107,047    250    164,595    3,562 
                     
OTHER EXPENSES                    
Interest expense   2,000    -    2,000    - 
                     
LOSS BEFORE INCOME TAX PROVISION   (109,047)   (250)   (166,595)   (3,562)
                     
INCOME TAX PROVISION   -    -    -    - 
                     
NET LOSS  $(109,047)   (250)  $(166,595)  $(3,562)
                     
Loss per share – basic and diluted  $(0.01)  $(0.00)  $(0.01)  $(0.00)
                     
Weighted average shares – basic and diluted   10,980,000    20,000,000    11,289,890    20,000,000 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

4
 

 

BIOSTAR ANGEL STEM CELL CORPORATION

(FORMERLY LILY GROVE ACQUISITION CORPORATION)

STATEMENTS OF CASH FLOWS

(UNAUDITED)

 

 

 

       For the period from 
   For the nine   May 17, 2017 
   months ended   (inception) to 
   September 30, 2018   September 30, 2017 
CASH FLOWS FROM OPERATING ACTIVITIES:          
           
Net loss  $(166,595)  $(3,562)
Adjustments to reconcile net loss to net cash used in operating activities:          
Expenses paid by stockholder and contributed as capital   3,000    312 
Common stock issued for services        2,000 
Changes in operating assets and liabilities:          
Increase in prepaid expenses   (3,052)   - 
Increase in accrued liabilities   24,831    1,250 
           
Net cash used in operating expenses   (141,816)   - 
           
CASH FLOWS FROM INVESTING ACTIVITIES:          
Due from a related party   (1,550)   - 
           
Net cash used in investing activities   (1,550)   - 
           
CASH FLOWS FROM FINANCING ACTIVITIES:          
Proceeds from loan from related parties   501,665      
Proceeds from issuance of common stock   1,048    - 
Proceeds from issuance of series A preferred stock   1,000    - 
           
Net cash provided by financing activities   503,713    - 
           
NET INCREASE IN CASH   360,347    - 
           
CASH, BEGINNING OF THE PERIOD   -    - 
           
CASH, END OF THE PERIOD  $360,347   $- 
           
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:          
Cash paid during the year for:          
Interest  $-   $- 
Income taxes  $-   $- 
           
SUPPLEMENTAL DISCLOSURE OF NON-CASH INVESTING AND FINANCING ACTIVITIES:          
Redemption of common shares in connection with change of control  $1,950   $- 

 

The accompanying notes are an integral part of these unaudited financial statements.

 

5
 

 

BIOSTAR ANGEL STEM CELL CORPORATION

(FORMERLY LILY GROVE ACQUISITION CORPORATION)

 

NOTES TO FINANCIAL STATEMENTS

(Unaudited)

 

 

 

1. NATURE OF OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

 

NATURE OF OPERATIONS

 

Biostar Angel Stem Cell Corporation (formerly Lily Grove Acquisition Corporation) (“the Company”) was incorporated on May 17, 2017 under the laws of the state of Delaware to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions. The Company has been in the developmental stage since inception and its operations to date have been limited to capital raising and debt financing activities, effecting a change in control, and the filing of a registration statement on Form 10 on September 11, 2017 with the Securities and Exchange Commission to register its class of common stock under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company will attempt to locate and negotiate with a business entity for the combination of that target company with the Company. We expect that the combination will take the form of a merger, stock-for-stock exchange or stock-for-assets exchange. We expect that the target company will wish to structure the business combination to be within the definition of a tax-free reorganization under Section 351 or Section 368 of the Internal Revenue Code of 1986, as amended. No assurances can be given that the Company will be successful in locating or negotiating a transaction with any target company. The Company has been formed to provide a method for a foreign or domestic private company to become a reporting company with a class of securities registered under the Exchange Act.

 

BASIS OF PRESENTATION

 

The summary of significant accounting policies presented below is designed to assist in understanding the Company’s financial statements. Such financial statements and accompanying notes are the representations of the Company’s management who are responsible for their integrity and objectivity. These accounting policies conform to accounting principles generally accepted in the United States of America (“GAAP”) in all material respects, and have been consistently applied in preparing the accompanying financial statements.

 

December 31 is the fiscal year end for the Company.

 

USE OF ESTIMATES

 

The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates, those difference could be material, and could have a material adverse effect on the Company, its financial condition, results of operations and stock price.

 

CASH AND CASH EQUIVALENTS

 

Cash and cash equivalents include cash on hand and on deposit at banking institutions as well as all highly liquid short-term investments with original maturities of 90 days or less. The Company had $360,347 of cash and cash equivalents as of September 30, 2018 and none as of December 31, 2017, respectively.

 

CONCENTRATION OF RISK

 

Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of cash and cash equivalents. The Company places its cash and cash equivalents with a FDIC insured banking institution. The FDIC deposit insurance coverage limit is $250,000 per depositor, per insured bank, for each account ownership category. These deposits may be redeemed upon demand. At September 30, 2018, the Company’s uninsured cash balances total $110,000.

 

6
 

 

INCOME TAXES

 

Under ASC 740, “Income Taxes,” deferred tax assets and liabilities are recognized for the future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Valuation allowances are established when it is more likely than not that some or all of the deferred tax assets will not be realized. As of September 30, 2018 and December 31, 2017 there were no deferred tax assets or liabilities due to the uncertainty of the realization of net operating losses prior to their expiration.

 

LOSS PER COMMON SHARE

 

Basic loss per common share excludes dilution and is computed by dividing net loss by the weighted average number of common shares outstanding during the period. Diluted loss per common share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock or resulted in the issuance of common stock that then shared in the loss of the entity. As of September 30, 2018 and December 31, 2017 there are no outstanding dilutive securities.

 

FAIR VALUE OF FINANCIAL INSTRUMENTS

 

The Company follows guidance for accounting for fair value measurements of financial assets and financial liabilities and for fair value measurements of nonfinancial items that are recognized or disclosed at fair value in the financial statements on a recurring basis. Additionally, the Company adopted guidance for fair value measurement related to nonfinancial items that are recognized and disclosed at fair value in the financial statements on a nonrecurring basis. The guidance establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to measurements involving significant unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy are as follows:

 

Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

 

Level 2 inputs are inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly.

 

Level 3 inputs are unobservable inputs for the asset or liability. The carrying amounts of financial assets such as cash and cash equivalents approximate their fair values because of the short maturity of these instruments.

 

2. GOING CONCERN

 

The Company has not generated any revenue since inception and has sustained operating losses of $107,047 during the three months ended September 30, 2018 and $164,595 during the nine months ended September 30, 2018. The Company had a working capital deficit of $164,547 and an accumulated deficit of $171,907 as of September 30, 2018 and a working capital deficit of $3,000 and an accumulated deficit of $5,312 as of December 31, 2017. The Company’s continuation as a going concern is dependent on its ability to generate sufficient cash flows from operations to meet its obligations and/or obtaining additional financing from its stockholders or other sources, as may be required.

 

The accompanying unaudited financial statements have been prepared assuming that the Company will continue as a going concern; however, the above condition raises substantial doubt about the Company’s ability to do so. The unaudited financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

 

In order to maintain its current level of operations, the Company will require additional working capital from either cash flow from operations or from the sale of its equity. However, the Company currently has no commitments from any third parties for the purchase of its equity. If the Company is unable to acquire additional working capital, it will be required to cease operations and will not continue as a going concern.

 

7
 

 

3. RECENT ACCOUNTING PRONOUNCEMENTS

 

In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business”. The amendments in this ASU clarify the definition of a business with the objective of adding guidance to assist entities with evaluating whether transactions should be accounted for as acquisitions (or disposals) of assets or businesses. These amendments provide a screen to determine when a set of assets and activities (a “set”) is not a business. If the screen is not met, the amendments in this ASU require that to be considered a business, first a set must include, at a minimum, an input and a substantive process that together significantly contribute to the ability to create output, and second, remove the evaluation of whether a market participant could replace missing elements. These amendments take effect for public businesses for fiscal years beginning after December 15, 2017 and interim periods within those periods, and all other entities should apply these amendments for fiscal years beginning after December 15, 2018, and interim periods within annual periods beginning after December 15, 2019. The Company does not expect that the adoption of this guidance will have a material impact on its financial statements.

 

In May 2017, the FASB issued ASU 2017-09, “Scope of Modification Accounting”, which amends the scope of modification accounting for share-based payment arrangements, provides guidance on the types of changes to the terms or conditions of share-based payment awards to which an entity would be required to apply modification accounting under ASC 718. The new guidance is effective as of January 1, 2018. The adoption of the standard did not have a material impact on the financial statements of the Company.

 

In November 2016, the FASB issued Accounting Standards Update No. 2016-18, “Statement of Cash Flows (Topic 230): Restricted Cash” (“ASU 2016-18”). The new guidance is intended to reduce diversity in practice by adding or clarifying guidance on classification and presentation of changes in restricted cash on the statement of cash flows. ASU 2016-18 is effective for annual and interim periods beginning after December 15, 2017. Early adoption is permitted. The amendments in this update should be applied retrospectively to all periods presented. Management believes that this ASU will only impact the Company if it has restricted cash in the future.

 

In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments” (“ASU 2016- 15”). ASU 2016-15 will make eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017. The new standard will require adoption on a retrospective basis unless it is impracticable to apply, in which case it would be required to apply the amendments prospectively as of the earliest date practicable. The adoption of the standard did not have a material impact on the financial statements of the Company.

 

Other recent accounting pronouncements issued by the FASB (including its Emerging Issues Task Force) and the United States Securities and Exchange Commission did not or are not believed by management to have a material impact on the Company’s present or future financial statements.

 

4. RELATED PARTY TRANSACTIONS

 

As of September 30, 2018, the Company had due $1,550 from Keewon Ra, Chief Executive Officer and Corporate Secretary and sole Director of the Company. The amount reflected the subscription payments received in Keewon Ra’s personal bank accounts in Korea for issuances of the Company’s common stock and preferred stock (see Note 7 for further explanation).

 

Amounts due to related parties were $1,665 as of September 30, 2018, which was due to Stemcellbio, Inc. Stemcellbio, Inc. paid operating expenses on behalf of the Company during the nine month period ended September 30, 2018. Stemcellbio, Inc. is a California corporation. Approximately 67% of Stemcellbio, Inc is owned by JASC Corporation, a Japanese Corporation. The father of Keewon Ra, is a significant shareholder of JASC Corporation.

 

5. ACCRUED LIABILITIES

 

As of September 30, 2018 and December 31, 2017, the Company had accrued interest and operating expenses of $27,831 and $3,000, respectively. The $27,831 accrued liabilities as of September 30, 2018 consist of $14,493 review and legal expenses, $11,338 payroll liabilities, and $2,000 accrued loan interest. The $3,000 accrued liabilities as of December 31, 2017 were audit expenses.

 

8
 

 

6. LOAN FROM AN AFFILIATE

 

On July 19, 2018, the Company borrowed $500,000 from JASC Corporation, a Japanese corporation. The father of Keewon Ra, Chief Executive Officer and Corporate Secretary and sole Director of the Company, is a significant shareholder of JASC Corporation. The borrowing is unsecured and matures on July 18, 2019. The borrowing bears interest at 2% per annum. $2,000 was accrued for interest as of September 30, 2018. Interest payments are due on December 31, 2018 and June 30, 2019, and the principal and the remaining interest is due on July 18, 2019. The Company borrowed the funds for working capital purposes.

 

7. STOCKHOLDERS’ DEFICIENCY

 

On January 15, 2018, the following events occurred to effect a change in control of the Company. The Company cancelled an aggregate of 19,500,000 shares of the then 20,000,000 shares of common stock outstanding. The then officers and directors of the Company, James Cassidy and James McKillop, resigned from the offices of President and director and Vice President and director respectively, held by them. Keewon Ra was named the sole Director of the Company and was named its Chief Executive Officer, Chief Financial Officer and Corporate Secretary.

 

On January 16, 2018, the Company issued 10,180,000 shares of its common stock to 16 shareholders at par value of $0.0001 per share for gross proceeds of $1,018 and issued 10,000,000 shares of its Series A Preferred stock at par value of $0.0001 per share for gross proceed of $1,000 to Jeong Chan Ra, the father of the Chief Executive Officer and Corporate Secretary and sole Director of the Company.

 

On April 30, 2018, the Company issued 30,000 shares of common stock to the Chief Executive Officer, Chief Financial Officer and Corporate Secretary and sole Director of the Company, Keewon Ra, at par value of $0.0001 per share for gross proceeds of $3. In addition, the Company issued 270,000 shares of common stock at par value of $0.0001 per share to 10 investors for gross proceeds of $27.

 

8. SUBSEQUENT EVENT

 

In accordance with FASB ASC Topic No. 855, Subsequent Events, the Company has evaluated subsequent events for recognition or disclosure through November 14, 2018, the date the accompanying financial statements were available to be issued and determined that there are no subsequent events requiring disclosure.

 

9
 

 

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

 

Forward-Looking Statements

 

This Quarterly Report on Form 10-Q includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). All statements other than statements of historical fact contained in this Quarterly Report, including statements regarding the future financial position, business strategy and plans and objectives of management for future operations, are forward-looking statements. The words “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “expect,” and similar expressions, as they relate to the Compay, are intended to identify forward-looking statements. We have based these forward-looking statements largely on current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions.

 

In addition, our business and financial performance may be affected by the factors that are discussed under “Risk Factors” in the Company’s registration statement on Form 10, filed with the Securities and Exchange Commission on September 11, 2017. New risk factors emerge from time to time and it is not possible for us to predict all risk factors, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially and adversely from those contained in any forward-looking statements.

 

You should not rely upon forward-looking statements as predictions of future events. We cannot assure you that the events and circumstances reflected in the forward-looking statements will be achieved or occur. Although we believe that the expectations reflected in the forward looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements.

 

The following discussion and analysis is qualified in its entirety by, and should be read in conjunction with, the more detailed information set forth in the financial statements and the notes thereto appearing elsewhere in this Quarterly Report on Form 10-Q. This discussion should not be construed to imply that the results discussed herein will necessarily continue into the future, or that any conclusion reached herein will necessarily be indicative of actual operating results in the future. Such discussion represents only the best present assessment of our management.

 

Overview

 

Biostar Angel Stem Cell Corporation (formerly Lily Grove Acquisition Corporation) (the “Company”) was incorporated on May 17, 2017 under the laws of the state of Delaware to engage in any lawful corporate undertaking, including, but not limited to, selected mergers and acquisitions.

 

On January 15, 2018, the Company effected a change of its control. The Company cancelled an aggregate of 19,500,000 shares of the then 20,000,000 shares of outstanding stock valued at par. James M. Cassidy resigned as the Company’s president, secretary and director and James McKillop resigned as the Company’s vice president and director. Keewon Ra was then named sole Director of the Company and was named Chief Executive Officer, Chief Financial Officer and Corporate Secretary of the Company.

 

Since inception, the Company’s operations have been limited to capital raising and debt financing activities, effecting the change in control described above, and the filing a registration statement on Form 10 on September 11, 2017 with the Securities and Exchange Commission to register its class of common stock under the Exchange Act.

 

The Company has no operations nor does it currently engage in any business activities generating revenues. The Company’s principal business objective is to achieve a business combination with a target company.

 

The Company expects that a business combination will take the form of a merger, stock-for-stock exchange or stock-for-assets exchange. The Company expects that the target company will wish to structure the business combination to be within the definition of a tax-free reorganization under Section 351 or Section 368 of the Internal Revenue Code of 1986, as amended.

 

No assurances can be given that the Company will be successful in negotiating with any target company.

 

10
 

 

In implementing a structure for a particular business acquisition, the Company may become a party to a merger, consolidation, reorganization, joint venture, licensing agreement or other arrangement with another corporation or entity. On the consummation of a transaction, the present management and shareholders of the Company may no longer be in control of the Company. In addition, the officers and director of the Company may, as part of the terms of the business combination, resign and be replaced by one or more new officers and directors.

 

Results of Operations

 

As of September 30, 2018, the Company had not generated any revenue since inception. The Company had sustained net loss of $166,595 and $3,562 for the nine months ended September 30, 2018 and for the period from May 17, 2017 (inception) to September 30, 2017. The Company had sustained net loss of $109,547 and $250 for the three months ended September 30, 2018 and 2017, respectively. The Company had an accumulated deficit of $171,907 and $5,312 as of September 30, 2018 and December 31, 2017, respectively. Operating expenses totaled $164,595 for the nine months ended September 30, 2018 compared to $3,562 for the period from May 17, 2017 (inception) to September 30, 2017, an increase of $161,033, or approximately 4,521%. The increase is attributable to salaries and additional accounting and legal professional service fees. Additionally, the Company was formed on May 17, 2017, and accordingly there were operations for only five months during the period ended September 30, 2017.

 

Financial Condition, Liquidity and Capital Resources

 

As of September 30, 2018, the Company had $360,347 in cash and cash equivalents.

 

On July 19, 2018, the Company borrowed $500,000 from JASC Corporation, a Japanese corporation. The father of the Company’s Chief Executive Officer and Corporate Secretary and sole Director, Keewon Ra, is a significant shareholder of JASC Corporation. The borrowing is unsecured and matures on July 18, 2019. The borrowing bears interest at 2% per annum. $2,000 was accrued for interest as of September 30, 2018. Interest payments are due on December 31, 2018 and June 30, 2019, and the principal and the remaining interest is due on July 18, 2019. The Company borrowed the funds for working capital purposes.

 

Going Concern Consideration

 

As reflected in the accompanying unaudited condensed financial statements, the Company has an accumulated deficit of $171,907 and a working capital deficit of $164,547. These raise substantial doubt about the Company’s ability to continue as a going concern. The ability of the Company to continue as a going concern is dependent on the Company’s ability to raise additional capital and implement its business plan. The financial statements do not include any adjustments that might be necessary if the Company is unable to continue as a going concern.

 

Operating Activities

 

Net cash used in operating activities for the nine months ended September 30, 2018 was $141,816, compared to $0 for the period from May 17, 2017 (inception) to September 30, 2017. The increase is attributable to salaries and additional accounting and legal professional service fees. Additionally, the Company was formed on May 17, 2017, and accordingly there were operations for only five months during the period ended September 30, 2017.

 

Investing Activities

 

Net cash used in investing activities for the nine months ended September 30, 2018 was $1,550 compared to $0 for the period from May 17, 2017 (inception) to September 30, 2017. The increase was due to the subscription payments received in Chief Executive Officer and Corporate Secretary and sole Director of the Company, Keewon Ra’s, personal bank accounts in Korea for issuances of the Company’s common stock and preferred stock.

 

11
 

 

Financing Activities

 

Net cash provided by financing activities for the nine months ended September 30, 2018 was $503,713 compared to $0 for the period from May 17, 2017 (inception) to September 30, 2017. The increase was due to proceeds received from loans from related parties of $501,665, and proceeds from investors for issuance of common stock of $1,048 and issuance of preferred stock of $1,000.

 

Equipment Financing

 

The Company has no existing equipment financing arrangements.

 

Alternative Financial Planning

 

The Company has no alternative financial plans at the moment. If the Company is not able to successfully raise monies as needed through a private placement or other securities offering (including, but not limited to, a primary public offering of securities), the Company’s ability to survive as a going concern and implement any part of its business plan or strategy will be severely jeopardized.

 

Off-Balance Sheet Arrangements

 

The Company has no off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on its financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources.

 

Critical Accounting Policies

 

The preparation of our condensed financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates, those difference could be material, and could have a material adverse effect on the Company, its financial condition, results of operations and stock price. Our accounting policies are described in Note 1 to our unaudited interim financial statements above.

 

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

 

Not applicable.

 

ITEM 4. CONTROLS AND PROCEDURES. DISCLOSURES AND PROCEDURES

 

Pursuant to rules adopted by the Securities and Exchange Commission, the Company carried out an evaluation of the effectiveness of the design and operation of its disclosure controls and procedures pursuant to the rules promulgated with respect to the Exchange Act. This evaluation was done as of the end of the period covered by this report under the supervision and with the participation of the Company’s principal executive officer and principal financial officer.

 

Based upon that evaluation, the Company’s principal executive officer and the Company’s principal financial officer believe that the Company’s disclosure controls and procedures are effective in gathering, analyzing and disclosing information needed to ensure that the information required to be disclosed by the Company in its periodic reports is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by an issuer in the reports that it files or submits under the Exchange Act is accumulated and communicated to the issuer’s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.

 

Changes in Internal Controls

 

There was no change in the Company’s internal control over financial reporting that was identified in connection with such evaluation that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

 

12
 

 

PART II OTHER INFORMATION

 

ITEM 1. LEGAL PROCEEDINGS

 

There are no legal proceedings against the Company and the Company is unaware of such proceedings contemplated against it.

 

ITEM 1A. RISK FACTORS

 

There have been no material changes from the risk factors disclosed in the Company’s registration statement on Form 10 filed with the Securities and Exchange Commission on September 11, 2017.

 

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

 

None.

 

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

 

None.

 

ITEM 4. MINE SAFETY DISCLOSURES

 

Not applicable.

 

ITEM 5. OTHER INFORMATION

 

None.

 

ITEM 6. EXHIBITS

 

(a)   Exhibits

 

10.1   Employment Agreement made and effective as of July 2, 2018 by and between Biostar Angel Stem Cell Corporation and Won Ho Chun (filed as Exhibit 10.1 to the Company’s Form 8-K filed with the SEC on July 3, 2018 and incorporated herein by reference)
     
31.1*   Rule 15d-14(a) Certification by Principal Executive Officer
     
31.2*   Rule 15d-14(a) Certification by Principal Financial Officer
     
32.1*   Section 1350 Certification of Principal Executive Officer and Principal Financial Officer
     
101.INS*   XBRL Instance Document
     
101.SCH*   XBRL Taxonomy Extension Schema Document
     
101.CAL*   XBRL Taxonomy Extension Calculation Linkbase Document
     
101.DEF*   XBRL Taxonomy Extension Definition Linkbase Document
     
101.LAB*   XBRL Taxonomy Extension Label Linkbase Document
     
101.PRE*   XBRL Taxonomy Extension Presentation Linkbase Document

 

* Filed herewith.

 

13
 

 

SIGNATURES

 

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized on the 16th day of November, 2018.

 

Signature   Title   Date
         
/s/ Keewon Ra   Chief Executive Officer and Corporate Secretary   November 16, 2018
Keewon Ra   (Principal Executive Officer)    
         
/s/ Won Ho Chun   Chief Financial Officer   November 16, 2018
Won Ho Chun   (Principal Financial Officer)    

 

14